Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised,... by Heinrich, Norbert, MD PhD, de Jager, Veronique, MBChB, Dreisbach, Julia, DVM, Gross-Demel, Petra, PhD, Schultz, Susanne, MD, Gerbach, Sina, PhD, Kloss, Florian, PhD, Dawson, Rodney, Prof, Narunsky, Kim, MD, Matt, Leoni, MD, Wildner, Leticia, PhD, McHugh, Timothy D, Prof, Fuhr, Uwe, Prof, Aldana, Brian H, MPh, Mouhdad, Chaima, PharmD, Brake, Lindsey te, PhD, Boeree, Martin J, Prof, Aarnoutse, Rob E, Prof, Svensson, Elin M, PhD, Gong, Xue, MSc, P J Phillips, Patrick, PhD, Diacon, Andreas H, MD, Hoelscher, Michael, Prof

Get full text

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles by Gillespie, Stephen H, Prof, DiNardo, Andrew R, PhD, Georghiou, Sophia B, PhD, Sabiiti, Wilber, PhD, Kohli, Mikashmi, PhD, Panzner, Ursula, MSc, Kontsevaya, Irina, PhD, Hittel, Norbert, PhD, Stuyver, Lieven J, PhD, Tan, Jia Bin, MSc, van Crevel, Reinout, PhD, Lange, Christoph, MD, Thuong, Thuong Nguyen Thuy, PhD, Heyckendorf, Jan, PhD, Ruhwald, Morten, PhD, Heinrich, Norbert, PhD

Get full text

Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials by Musisi, Emmanuel, PhD, Wyness, Adam, PhD, Eldirdiri, Sahar, MD, Dombay, Evelin, PhD, Mtafya, Bariki, PhD, Ntinginya, Nyanda E, PhD, Heinrich, Norbert, Prof, Kibiki, Gibson S, Prof, Hoelscher, Michael, PhD, Boeree, Martin, Prof, Aarnoutse, Rob, Prof, Gillespie, Stephen H, Prof, Sabiiti, Wilber, PhD

Get full text